Study guide

GI, GU, Nutrition, and Hydration Supportive Care

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

GI, GU, Nutrition, and Hydration Supportive Care

Key Takeaways Explain This Topic AI

Chemotherapy-induced nausea/vomiting is classified as acute (<24h), delayed (>24h), anticipatory, breakthrough, and refractory; control is best when antiemetics are given prophylactically by regimen emetogenicity.

Highly emetogenic regimens warrant triple/quadruple prophylaxis (5-HT3 antagonist + NK-1 antagonist + dexamethasone +/- olanzapine).

Diarrhea is graded by stools above baseline; immune-checkpoint colitis and CPT-11 (irinotecan) diarrhea have distinct management.

Cancer cachexia is inflammation-driven metabolic wasting, not simple starvation, and is not fully reversible by forcing calories.

GU red flags include hemorrhagic cystitis from cyclophosphamide/ifosfamide (mesna and hydration prevent it), urinary obstruction, and immunotherapy nephritis.

Last updated: October 2026

  • GI, GU, Nutrition, and Hydration Supportive Care
  • Chemotherapy-Induced Nausea and Vomiting (CINV)

GI symptoms are the most common reason oncology patients call between visits, and chemotherapy-induced nausea and vomiting (CINV) is high-yield on the OCN. Memorize the five types, because prophylaxis differs:

  • CINV type Timing/trigger Key point
  • Acute Within 24 h of chemo Peaks 5-6 h; serotonin-mediated
  • Delayed 24-120 h after chemo Substance P/NK-1 mediated; cisplatin, AC
  • Anticipatory Before the next dose Conditioned response; lorazepam, behavioral
  • Breakthrough Despite prophylaxis Add a different-class rescue agent
  • Refractory Failed prior cycles Re-evaluate regimen and adherence

The principle is prophylaxis before emesis starts , matched to regimen emetogenicity. Highly emetogenic regimens (cisplatin, AC) get a 5-HT3 antagonist (ondansetron, palonosetron) + NK-1 antagonist (aprepitant/fosaprepitant) + dexamethasone , often with olanzapine . Moderate regimens use a 5-HT3 antagonist plus dexamethasone. Teach scheduled versus as-needed dosing, timing before infusion, and when to call. Escalate persistent vomiting, inability to keep fluids down for 24 hours, confusion, or dehydration signs.

Diarrhea, Constipation, and Mucositis

Symptom RN assessment Supportive focus

Diarrhea Stools above baseline, blood, fever, cramping, hydration Loperamide per protocol, fluids, rule out C. difficile/colitis, skin care

Constipation Last BM, opioids, intake, distention/vomiting Scheduled stimulant laxative (e.g., senna) bowel regimen, mobility, hydration

Mucositis Oral pain, ulcers, intake, infection Bland saline/baking-soda rinses, pain control, avoid alcohol mouthwash

Know two named diarrhea patterns: irinotecan (CPT-11) causes early cholinergic diarrhea (treated with atropine) and late secretory diarrhea (high-dose loperamide); immune-checkpoint colitis can be severe and is treated with corticosteroids, not antimotility agents alone. CTCAE grades diarrhea by stools above baseline (Grade 1: <4/day; Grade 3: >=7/day or hospitalization indicated). Opioid-induced constipation is predictable and is prevented , not just treated, with a scheduled stimulant laxative such as senna, started with the opioid; adding a stool softener offers no further benefit.

Nutrition, Hydration, and Cachexia

Assess usual weight, recent loss, appetite, dysphagia, dentition, taste change, food access, cost, and caregiver support. Refer to a dietitian early for unintentional weight loss (a loss of >=5% in one month or >=10% in six months is a malnutrition red flag), poor intake, enteral/parenteral needs, or head-and-neck/esophageal/pancreatic/gastric disease. Practical teaching: small frequent high-protein meals, oral supplements, bland foods for nausea, and team-set hydration goals.

Critically, cancer cachexia is an inflammatory, metabolic wasting syndrome driven by cytokines, not simple starvation, so it is not fully reversed by forcing calories. Explaining this reduces caregiver blame and guilt. Do not push oral intake when obstruction, severe dysphagia, aspiration risk, or end-of-life goals call for a different plan.

GU Symptoms and Renal Safety

GU concerns include dysuria, retention, hematuria, incontinence, sexual-health changes, and renal impairment. A named emergency is hemorrhagic cystitis from cyclophosphamide and ifosfamide , prevented with aggressive hydration and mesna (which binds the toxic metabolite acrolein); teach the patient to void frequently and report pink or bloody urine. Other GU risks: obstructive tumors, immunotherapy nephritis (rising creatinine), and radiation cystitis/proctitis. Escalate inability to urinate, gross hematuria with clots, fever with urinary symptoms, flank pain, sudden creatinine rise, or confusion.

Reassess every intervention: did the antiemetic work, did stool frequency fall, is the patient urinating, is weight stabilizing, and were supplies obtained before discharge.

Mucositis and Oral Care in Depth

Oral and gastrointestinal mucositis is among the most distressing toxicities, peaking around 7-14 days after many regimens and after head-and-neck radiation. Because the mucosal barrier breaks down while counts are low, mucositis is both a comfort problem and an infection portal. The cornerstone is a structured oral-care protocol: brushing with an extra-soft brush, frequent bland rinses (normal saline or a salt-and-baking-soda solution every few hours), and removal of dentures when they irritate.

The nurse teaches patients to avoid alcohol-based mouthwash, tobacco, hot or spicy foods, and acidic juices, all of which sting and worsen breakdown. Pain control may include topical agents and systemic analgesics, and severe mucositis that prevents swallowing can require IV hydration or nutrition support. Watch for white plaques or a sudden pain change suggesting candidiasis or herpes simplex reactivation, which need antifungal or antiviral therapy, not just comfort measures.

Hydration, Electrolytes, and the High-Risk Patient

Dehydration is a final common pathway for many GI and GU problems and quietly undermines treatment. The nurse tracks intake and output, daily weights when available, mucous-membrane moisture, capillary refill, orthostatic vitals, and trends in sodium, potassium, magnesium, and creatinine. Vomiting and diarrhea deplete potassium and magnesium; obstruction and renal injury can elevate them. A patient with an ileostomy, severe mucositis, head-and-neck radiation, or repeated vomiting can decompensate within a day, so the threshold for same-day evaluation is low.

Teach realistic home goals such as sipping oral rehydration fluids steadily, using anti-emetics before meals, and calling when fluids will not stay down for more than a few hours. Effective supportive care intervenes before the patient arrives in the emergency department dehydrated, hypokalemic, and too weak to continue therapy, which is the outcome these OCN questions are designed to help nurses prevent.

A practical rule the exam rewards is to quantify rather than accept vague reports: ten watery stools with dizziness, or vomiting that has prevented any fluids for twelve hours, defines urgency far better than the word diarrhea or vomiting alone, and the documented numbers drive both the triage decision and the provider's orders.